Long-Term Analysis of Efficacy and Toxicidad of Zoledroinic Acid in Patients with Multiple Myeloma

Myeloma bone disease MBD) is the most common and dangerous effects in patients with multiple myeloma. Bisphosphonates (BP), are the treatment of choice. But efficacy and adverse events has not been evaluated at longer follow-up. Thus, we review our experience in a tertiary cancer center, whose received zoledronic acid (ZO): in a large number of cases (1041) and longer follow-up: 4.2 to 21.6 years (median 13.8).Skeletal event (SE) were statistically better in patients who received ZA : 52 events :8.96%,compared to 207 (42.6) p < 0.001 in patients whose did not received ZA, independently if the patients received autologous stem cell transplant or not. But progression free survival and overall survival did not show any benefit. Adverse events were minimal, and jaw necrosis were not observed. Thus, we considered that ZA, remain to be the best treatment of MBD, but we confirm that ZA did not show at longer follow-up any antitumor effect.